Chimeric antigen receptor-modified T-cell (CAR-T) therapy is a novel immunotherapy approach that has achieved remarkable success in the treatment of a variety of hematological malignancies.
The basis of CAR-T therapy is to make the immune system attack cancer cells. Briefly, patient T cells are isolated and genetically engineered to express a chimeric antigen receptor (CAR) that recognizes specific tumor-associated antigens (TAAs) such as CD19, a cell surface protein that is uniformly and strongly expressed on malignant B cells. Two new FDA-approved CD19-specific drugs, KymriahTM and YescartaTM, demonstrate the importance of TAAs in CAR-T cell therapy research.
Utilizing our SAMSTM platform, KACTUS has developed a series of recombinant proteins covering multiple CAR-T cell therapeutic targets, including some difficult-to-express proteins such as CD19 and BCMA.
KACTUS provides various types of highly active CAR-T target antigen proteins, including site-directed labeled proteins, fluorescent labeled proteins, biotin-labeled proteins, etc., which can flexibly meet different research and development needs such as CAR-T positive rate detection.
Use Human CD19-FITC Compatible protein to detect the expression rate of Anti-CD19-CAR positive cells. Non-transfected 293T cells and FITC-labeled protein control were used as negative control.